Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

118.39 -2.33 (-1.93%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
65 66 Next >
Pfizer/BioNTech Seek FDA Emergency Nod For Updated COVID-19 Shot For Kids Under 11 Years
Via Benzinga
Pfizer CEO Contracts COVID-19 Infection For Second Time
Pfizer Inc's (NYSE: PFE) CEO Albert Bourla said he had tested positive for COVID-19. 
Via Benzinga
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Kids, But Scrambles Supply Challenges
Last week, Moderna Inc (NASDAQ: MRNA) said it asked the FDA to authorize the use of its updated booster shot in children ages 6 to 17. The company expects to complete a request for the use of the... 
Via Benzinga
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
From Pfizer Inc.
Via Business Wire
Pfizer Starts Pivotal Phase 3 Study of mRNA-Based Influenza Vaccine
Via Benzinga
Switzerland To Dispose 10M Expired COVID-19 Vaccine Doses From Moderna
Via Benzinga
Why Is Novavax (NVAX) Stock Falling Today?
Novavax still has cash, but it needs to get approval for another vaccine if NVAX stock is to be worth buying again. 
Via InvestorPlace
Nikola, Super Micro Computer And Other Big Losers From Monday
U.S. stocks closed higher with the Dow Jones gaining around 197 points on Monday. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Check Out What Whales Are Doing With BNTX
Someone with a lot of money to spend has taken a bullish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
Why Are Vaccine Stocks MRNA, PFE, NVAX, BNTX Down Today?
Vaccine stocks are taking it on the chin following President Joe Biden's comments that the "pandemic is over." What now? 
Via InvestorPlace
Why BioNTech, Moderna And Novavax Shares Are Diving
BioNTech SE - ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA) and Novavax, Inc. (NASDAQ: NVAX) are all trading lower during Mo 
Via Benzinga
The Silver Lining For Pfizer, Moderna In This Month's IBD/TIPP Poll
The companies recently launched their updated Covid booster shots. 
Via Investor's Business Daily
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
Via Benzinga
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
From Pfizer Inc.
Via Business Wire
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
Via Benzinga
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report
Via Benzinga
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
Via Benzinga
Moderna, BioNTech Jump After CDC Green-Lights Updated Covid Boosters
These new shots target the BA.4 and BA.5 subvariants of omicron. 
Via Investor's Business Daily
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Europe Backs Approval Of Omicron-Adapted COVID-19 Vaccines
Health Canada has approved Moderna Inc's (NASDAQ: 
Via Benzinga
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
From Pfizer Inc.
Via Business Wire
Top Financial Stories Thursday, September 1: Netflix Weighs Charging High Sum For Ads, Self Harm posts Grow On Twitter, California Fast-Food Bill Faces Industry Backlash...
Wall Street Journal 
Via Benzinga
Why Novavax Shares Are Getting Hammered After Moderna, Pfizer And BioNTech News
Novavax, Inc. (NASDAQ: NVAX) shares are trading lower by 6.76% to $32.84 Wednesday afternoon in possible reaction to competitor Moderna Inc (NASDAQ: MRNA) receiving FDA authorization for emergency use... 
Via Benzinga
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
From Pfizer Inc.
Via Business Wire
Pfizer, Moderna Nab FDA Authorization For Updated Covid Boosters
Boosters are recommended two months out from the last shot. 
Via Investor's Business Daily
Benzinga Before The Bell: Tesla Sues Louisiana Automobile Dealers Association, Will iPhone 14 Feature Satellite Connectivity?, Netflix Denies $7 To $9 Ad-Supported Plan And Other Top Financial Stories Tuesday, August 30
Reuters Taiwan’s China Airlines Orders 16 Boeing 787s 
Via Benzinga
US Stock Futures Higher Ahead Of Economic Data, Fed Speakers
Pre-open movers U.S. stock futures traded higher in early pre-market trade as investors digested comments from Federal Reserve Chairman Jerome Powell. Markets closed lower again on Monday, with the... 
Via Benzinga
Pfizer-BioNTech, Moderna Set To Get FDA Nod For Omicron Booster Shots As Early As Wednesday: Report
Booster shots for Omicron variants of the novel coronavirus could officially be made available in the U.S. just after Labor Day, Politico reported on Monday. 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Pfizer/BioNTech Complete European Submission For Omicron Subvariant Adapted Vaccine
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.